Do analysts recommend CVAC or FHTX?

Foghorn Therapeutics has a consensus target price of $11.43, indicating a potential upside of 162.12%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Foghorn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Foghorn Therapeutics (FHTX) Competitors

$4.36 -0.06 (-1.36%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$4.36 0.00 (0.00%)

As of 09/14/2026 07:30 PM Eastern

Compare

FHTX vs. SANA, SVRA, SLDB, CVAC, and FTH

Should you buy Foghorn Therapeutics stock or one of its competitors? Foghorn Therapeutics's main competitors and comparable companies include Sana Biotechnology (SANA), Savara (SVRA), Solid Biosciences (SLDB), CureVac (CVAC), and Sensei Biotherapeutics (FTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Foghorn Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Sana Biotechnology has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

In the previous week, Sana Biotechnology had 7 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 8 mentions for Sana Biotechnology and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.87 beat Sana Biotechnology's score of 0.59 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sana Biotechnology	Positive
Foghorn Therapeutics	Very Positive

Sana Biotechnology has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.86, meaning that its share price is 186% more volatile than the broader market.

Sana Biotechnology currently has a consensus price target of $9.33, suggesting a potential upside of 191.67%. Foghorn Therapeutics has a consensus price target of $11.43, suggesting a potential upside of 162.12%. Given Sana Biotechnology's higher possible upside, equities research analysts plainly believe Sana Biotechnology is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Foghorn Therapeutics has higher revenue and earnings than Sana Biotechnology. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Foghorn Therapeutics	$36.74M	7.05	-$74.28M	-$0.98	N/A

Summary

Sana Biotechnology beats Foghorn Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Savara?

Foghorn Therapeutics (NASDAQ:FHTX) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Savara has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
Savara	N/A	-90.28%	-68.95%

In the previous week, Savara had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 2 mentions for Savara and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.87 beat Savara's score of 1.84 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Foghorn Therapeutics	Very Positive
Savara	Very Positive

Foghorn Therapeutics has a beta of 2.86, suggesting that its share price is 186% more volatile than the broader market. Comparatively, Savara has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

61.5% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Foghorn Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$36.74M	7.05	-$74.28M	-$0.98	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Foghorn Therapeutics currently has a consensus target price of $11.43, indicating a potential upside of 162.12%. Savara has a consensus target price of $10.00, indicating a potential upside of 87.27%. Given Foghorn Therapeutics' higher probable upside, research analysts plainly believe Foghorn Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Foghorn Therapeutics beats Savara on 9 of the 13 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Solid Biosciences has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Solid Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the broader market.

Foghorn Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Foghorn Therapeutics	$36.74M	7.05	-$74.28M	-$0.98	N/A

Solid Biosciences currently has a consensus price target of $18.75, indicating a potential upside of 114.53%. Foghorn Therapeutics has a consensus price target of $11.43, indicating a potential upside of 162.12%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Solid Biosciences had 6 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 7 mentions for Solid Biosciences and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.87 beat Solid Biosciences' score of 0.89 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Solid Biosciences	Positive
Foghorn Therapeutics	Very Positive

Summary

Foghorn Therapeutics beats Solid Biosciences on 12 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

CureVac has a net margin of 199.92% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

17.3% of CureVac shares are held by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the broader market.

Foghorn Therapeutics has a consensus target price of $11.43, indicating a potential upside of 162.12%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

CureVac has higher revenue and earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Foghorn Therapeutics	$36.74M	7.05	-$74.28M	-$0.98	N/A

In the previous week, Foghorn Therapeutics had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Foghorn Therapeutics and 0 mentions for CureVac. Foghorn Therapeutics' average media sentiment score of 1.87 beat CureVac's score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Foghorn Therapeutics	Very Positive

Summary

Foghorn Therapeutics beats CureVac on 10 of the 17 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Sensei Biotherapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

61.5% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Sensei Biotherapeutics had 7 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 8 mentions for Sensei Biotherapeutics and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.87 beat Sensei Biotherapeutics' score of 0.44 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Foghorn Therapeutics	Very Positive
Sensei Biotherapeutics	Neutral

Foghorn Therapeutics presently has a consensus target price of $11.43, indicating a potential upside of 162.12%. Sensei Biotherapeutics has a consensus target price of $55.00, indicating a potential upside of 40.70%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Foghorn Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Sensei Biotherapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

Sensei Biotherapeutics has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$36.74M	7.05	-$74.28M	-$0.98	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Foghorn Therapeutics has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.28, indicating that its stock price is 128% less volatile than the broader market.

Summary

Foghorn Therapeutics beats Sensei Biotherapeutics on 10 of the 15 factors compared between the two stocks.

Get Foghorn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FHTX vs. The Competition

Export

Metric	Foghorn Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$262.48M	$3.86B	$7.15B	$13.98B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-4.45	14.33	272.99	25.37
Price / Sales	7.05	1,347.73	617.33	75.94
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	-2.27	15.26	10.43	6.24
Net Income	-$74.28M	-$22.78M	$3.49B	$358.08M
7 Day Performance	-9.73%	-0.79%	-1.15%	-0.70%
1 Month Performance	-30.35%	2.12%	0.56%	-2.76%
1 Year Performance	-12.63%	41.90%	20.17%	6.72%

Foghorn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FHTX Foghorn Therapeutics	2.4021 of 5 stars	$4.36 -1.4%	$11.43 +162.1%	-16.0%	$262.48M	$36.74M	N/A	106	Positive News
SANA Sana Biotechnology	2.8751 of 5 stars	$3.45 -10.4%	$9.33 +170.5%	-0.6%	$1.15B	N/A	N/A	380	High Trading Volume
SVRA Savara	2.1506 of 5 stars	$5.53 +3.0%	$10.14 +83.4%	+50.0%	$1.10B	N/A	N/A	20	Positive News
SLDB Solid Biosciences	2.5635 of 5 stars	$9.93 -3.1%	$18.18 +83.1%	+62.2%	$1.10B	N/A	N/A	100	News Coverage Analyst Forecast Gap Down
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FHTX) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. SANA, SVRA, SLDB, CVAC, and FTH

How does Foghorn Therapeutics compare to Sana Biotechnology?

Summary

How does Foghorn Therapeutics compare to Savara?

Summary

How does Foghorn Therapeutics compare to Solid Biosciences?

Summary

How does Foghorn Therapeutics compare to CureVac?

Summary

How does Foghorn Therapeutics compare to Sensei Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. SANA, SVRA, SLDB, CVAC, and FTH

How does Foghorn Therapeutics compare to Sana Biotechnology?

Is SANA or FHTX more profitable?

Does the media refer more to SANA or FHTX?

Which has more volatility and risk, SANA or FHTX?

Do analysts recommend SANA or FHTX?

Do insiders & institutionals hold more shares of SANA or FHTX?

Which has higher valuation and earnings, SANA or FHTX?

Summary

How does Foghorn Therapeutics compare to Savara?

Is FHTX or SVRA more profitable?

Does the media prefer FHTX or SVRA?

Which has more risk and volatility, FHTX or SVRA?

Do institutionals and insiders believe in FHTX or SVRA?

Which has stronger earnings and valuation, FHTX or SVRA?

Do analysts prefer FHTX or SVRA?

Summary

How does Foghorn Therapeutics compare to Solid Biosciences?

Is SLDB or FHTX more profitable?

Do insiders and institutionals believe in SLDB or FHTX?

Which has more risk & volatility, SLDB or FHTX?

Which has stronger earnings & valuation, SLDB or FHTX?

Do analysts recommend SLDB or FHTX?

Does the media favor SLDB or FHTX?

Summary

How does Foghorn Therapeutics compare to CureVac?

Is CVAC or FHTX more profitable?

Do institutionals & insiders believe in CVAC or FHTX?

Which has more risk and volatility, CVAC or FHTX?

Do analysts recommend CVAC or FHTX?

Which has better valuation & earnings, CVAC or FHTX?

Does the media favor CVAC or FHTX?

Summary

How does Foghorn Therapeutics compare to Sensei Biotherapeutics?

Do institutionals and insiders believe in FHTX or FTH?

Does the media prefer FHTX or FTH?

Do analysts prefer FHTX or FTH?

Is FHTX or FTH more profitable?

Which has better earnings and valuation, FHTX or FTH?

Which has more volatility and risk, FHTX or FTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools